265 related articles for article (PubMed ID: 28939740)
1. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Pili R; Quinn DI; Hammers HJ; Monk P; George S; Dorff TB; Olencki T; Shen L; Orillion A; Lamonica D; Fragomeni RS; Szabo Z; Hutson A; Groman A; Perkins SM; Piekarz R; Carducci MA
Clin Cancer Res; 2017 Dec; 23(23):7199-7208. PubMed ID: 28939740
[No Abstract] [Full Text] [Related]
2. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
3. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
Garcia JA; Mekhail T; Elson P; Triozzi P; Nemec C; Dreicer R; Bukowski RM; Rini BI
BJU Int; 2011 Feb; 107(4):562-70. PubMed ID: 20840548
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
Dandamudi UB; Ghebremichael M; Sosman JA; Clark JI; McDermott DF; Atkins MB; Dutcher JP; Urba WJ; Regan MM; Puzanov I; Crocenzi TS; Curti BD; Vaishampayan UN; Crosby NA; Margolin KA; Ernstoff MS
J Immunother; 2013; 36(9):490-5. PubMed ID: 24145360
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
[TBL] [Abstract][Full Text] [Related]
8. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Procopio G; Verzoni E; Bracarda S; Ricci S; Sacco C; Ridolfi L; Porta C; Miceli R; Zilembo N; Bajetta E
Br J Cancer; 2011 Apr; 104(8):1256-61. PubMed ID: 21448165
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
12. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
16. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Pili R; Liu G; Chintala S; Verheul H; Rehman S; Attwood K; Lodge MA; Wahl R; Martin JI; Miles KM; Paesante S; Adelaiye R; Godoy A; King S; Zwiebel J; Carducci MA
Br J Cancer; 2017 Mar; 116(7):874-883. PubMed ID: 28222071
[TBL] [Abstract][Full Text] [Related]
17. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
[TBL] [Abstract][Full Text] [Related]
19. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
Peterson AC; Harlin H; Karrison T; Vogelzang NJ; Knost JA; Kugler JW; Lester E; Vokes E; Gajewski TF; Stadler WM;
Invest New Drugs; 2006 Mar; 24(2):141-9. PubMed ID: 16514482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
